Ten-Day Vonoprazan-Amoxicillin Dual Therapy vs Standard 14-Day Bismuth-Based Quadruple Therapy for First-Line Helicobacter pylori Eradication: A Multicenter Randomized Clinical Trial

医学 阿莫西林 内科学 养生 幽门螺杆菌 意向治疗分析 不利影响 胃肠病学 随机对照试验 抗生素 微生物学 生物
作者
Tian‐Lian Yan,Jinghua Wang,Xinjue He,Ya-bi Zhu,Lin-Jie Lu,Yan-Jiao Wang,Ziwei Wang,Jianguo Gao,Chengfu Xu,Hong Zhang,Shuang-mei Luan,Lan Li,Yi Chen
出处
期刊:The American Journal of Gastroenterology [American College of Gastroenterology]
被引量:12
标识
DOI:10.14309/ajg.0000000000002592
摘要

INTRODUCTION: Whether 10-day short-course vonoprazan-amoxicillin dual therapy (VA-dual) is noninferior to the standard 14-day bismuth-based quadruple therapy (B-quadruple) against Helicobacter pylori eradication has not been determined. This trial aimed to compare the eradication rate, adverse events, and compliance of 10-day VA-dual regimen with standard 14-day B-quadruple regimen as first-line H. pylori treatment. METHODS: This prospective randomized clinical trial was performed at 3 institutions in eastern China. A total of 314 treatment-naive, H. pylori –infected patients were randomly assigned in a 1:1 ratio to either 10-day VA-dual group or 14-day B-quadruple group. Eradication success was determined by 13 C-urea breath test at least 4 weeks after treatment. Eradication rates, adverse events, and compliance were compared between groups. RESULTS: Eradication rates of VA-dual and B-quadruple groups were 86.0% and 89.2% ( P = 0.389), respectively, by intention-to-treat (ITT) analysis; 88.2% and 91.5% ( P = 0.338), respectively, by modified ITT analysis; and 90.8% and 91.3% ( P = 0.884), respectively, by per-protocol (PP) analysis. The efficacy of the VA-dual remained noninferior to B-quadruple therapy in all ITT, modified ITT, and PP analyses. The incidence of adverse events in the VA-dual group was significantly lower compared with that in the B-quadruple group ( P < 0.001). Poor compliance contributed to eradication failure in the VA-dual group ( P < 0.001), while not in the B-quadruple group ( P = 0.110). DISCUSSION: The 10-day VA-dual therapy provided satisfactory eradication rates of >90% (PP analysis) and lower rates of adverse events compared with standard 14-day B-quadruple therapy as first-line H. pylori therapy. TRAIL REGISTRATION NUMBER: ChiCTR2300070100.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
研友_VZG7GZ应助科研通管家采纳,获得10
刚刚
大个应助科研通管家采纳,获得30
1秒前
1秒前
李爱国应助科研通管家采纳,获得50
1秒前
脑洞疼应助科研通管家采纳,获得10
1秒前
hhhbbb完成签到,获得积分10
2秒前
3秒前
3秒前
4秒前
xiaocai发布了新的文献求助10
4秒前
稚久发布了新的文献求助10
4秒前
5秒前
李健的小迷弟应助六六采纳,获得10
5秒前
cocu117完成签到 ,获得积分10
6秒前
欢呼的冰蝶完成签到,获得积分10
7秒前
Lucas应助Abner采纳,获得30
7秒前
8秒前
10秒前
科研通AI2S应助Emmmm采纳,获得10
10秒前
cc发布了新的文献求助10
10秒前
小羊发布了新的文献求助10
10秒前
11秒前
多情孤兰完成签到,获得积分20
11秒前
14秒前
vg完成签到 ,获得积分10
14秒前
如意巧凡发布了新的文献求助10
15秒前
满意的青寒完成签到 ,获得积分10
15秒前
CuSO4完成签到,获得积分10
15秒前
16秒前
16秒前
17秒前
18秒前
jin完成签到 ,获得积分10
18秒前
肉卷完成签到 ,获得积分10
19秒前
田様应助大力的隶采纳,获得10
19秒前
单纯新梅发布了新的文献求助10
19秒前
脑洞疼应助121采纳,获得10
19秒前
20秒前
晨初发布了新的文献求助10
20秒前
21秒前
高分求助中
Sustainability in Tides Chemistry 2000
Microlepidoptera Palaearctica, Volumes 1 and 3 - 13 (12-Volume Set) [German] 1122
Дружба 友好报 (1957-1958) 1000
The Data Economy: Tools and Applications 1000
A Dissection Guide & Atlas to the Rabbit 600
中国心血管健康与疾病报告2023(要完整的报告) 500
Development of a new synthetic process for the synthesis of (S)-methadone and (S)- and (R)-isomethadone as NMDA receptor antagonists for the treatment of depression 500
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 基因 遗传学 催化作用 物理化学 免疫学 量子力学 细胞生物学
热门帖子
关注 科研通微信公众号,转发送积分 3102764
求助须知:如何正确求助?哪些是违规求助? 2754003
关于积分的说明 7626148
捐赠科研通 2406815
什么是DOI,文献DOI怎么找? 1277007
科研通“疑难数据库(出版商)”最低求助积分说明 617041
版权声明 599103